UNSPSC 51413603: Carprazidil

This classification denotes a vasodilating agent with the molecular formula C12H13N5O4, a preparation that US FDA regulates as an active ingredient or moiety under Unique Ingredient Identifier O55EMK06L9, chemically known as methyl 5-(3,6-dihydro-1(2h)-pyridyl)-2-oxo-2h-(1,2,4)oxadiazolo(2,3-a)pyrimidine-7-carbamate but generally known as carprazidil, which bears US NIH Compound Identifier 68875. European Medicines Agency schedules Carprazidil in its eXtended EudraVigilance Medicinal Product Dictionary or XEVMPD under Index SUB06143MIG.

UNSPSC 51413603 Carprazidil, a Commodity code, captures state and local procurement of advanced life support and emergency medications supplied to fire rescue services, health agencies, and pharmacy benefit programs. State and local governments buy emergency cardiac and critical-care medications—epinephrine, labetalol, adenosine, diltiazem, and related injectables—through sealed competitive bids, cooperative purchasing agreements, and RFIs that establish supply relationships with manufacturers and authorized wholesalers. Issuing bodies include city purchasing departments procuring for fire rescue operations, state health and human services commissions managing pharmacy benefit programs, and multistate cooperative purchasing alliances coordinating pharmaceutical supply across participating jurisdictions. The work spans goods procurement with strict regulatory and shelf-life compliance, including FDA requirements, cGMP certification, Drug Supply Chain Security Act (DSCSA) compliance, OSHA Hazard Communication Standards (HCS) documentation, and expiration-date warranties of nine months or more from acceptance.

Recent activity appears concentrated in Florida and Minnesota. The City of Tampa issued IFB 26P00188 in April 2026 for Advanced Life Support Medications to supply Tampa Fire Rescue in Hillsborough County, with sealed-bid deadline April 8, 2026 and an estimated contract value of $40,000, featuring a 5 percent bid discount for Small Local Business Enterprise participation. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP), administered by the Minnesota Department of Administration's Office of State Procurement, issued RFP S1070000015802 in January 2026 for generic multi-source pharmaceuticals and OTC products distributed across participating state and local government facilities including Oregon, with proposals due March 26, 2026, and awarded vendor provision to authorized wholesalers by May 15, 2026. The Texas Health and Human Services Commission issued RFI HHS0017013 in March 2026 as a preliminary market-intelligence phase to explore direct-to-manufacturer prescription fulfillment and pharmacy benefit management strategies, with no award value specified at the RFI stage.